HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 195 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,695,345 | +10.9% | 646,475 | +4.7% | 0.60% | +16.0% |
| Q2 2023 | $22,276,652 | +15.8% | 617,595 | +22.6% | 0.52% | -8.3% |
| Q1 2023 | $19,236,647 | -41.1% | 503,709 | -12.3% | 0.57% | -38.6% |
| Q4 2022 | $32,671,639 | +28.0% | 574,194 | -11.1% | 0.92% | +22.6% |
| Q3 2022 | $25,534,000 | -3.6% | 645,773 | +7.3% | 0.75% | +1.3% |
| Q2 2022 | $26,488,000 | +18.2% | 602,011 | +7.1% | 0.74% | +40.0% |
| Q1 2022 | $22,415,000 | +3.3% | 562,050 | +4.1% | 0.53% | +16.0% |
| Q4 2021 | $21,703,000 | -2.7% | 539,742 | -1.6% | 0.46% | -8.6% |
| Q3 2021 | $22,316,000 | +39.2% | 548,583 | +55.4% | 0.50% | +45.3% |
| Q2 2021 | $16,033,000 | +8.2% | 353,079 | -0.7% | 0.34% | +15.4% |
| Q1 2021 | $14,820,000 | +4.4% | 355,477 | +6.9% | 0.30% | -7.2% |
| Q4 2020 | $14,199,000 | +61.6% | 332,456 | -0.6% | 0.32% | +27.4% |
| Q3 2020 | $8,786,000 | -2.6% | 334,305 | -0.7% | 0.25% | -3.4% |
| Q2 2020 | $9,023,000 | +46.0% | 336,559 | -2.0% | 0.26% | +15.0% |
| Q1 2020 | $6,180,000 | +51.4% | 343,541 | +49.2% | 0.23% | +127.0% |
| Q4 2019 | $4,083,000 | +57.3% | 230,288 | +37.6% | 0.10% | +56.2% |
| Q3 2019 | $2,596,000 | -14.9% | 167,346 | -5.7% | 0.06% | -11.1% |
| Q2 2019 | $3,050,000 | -46.7% | 177,520 | -50.0% | 0.07% | +5.9% |
| Q1 2019 | $5,720,000 | +65.6% | 355,322 | +50.5% | 0.07% | -20.9% |
| Q4 2018 | $3,454,000 | -68.0% | 236,066 | -60.3% | 0.09% | -57.2% |
| Q3 2018 | $10,803,000 | +5.3% | 594,534 | -2.2% | 0.20% | +5.2% |
| Q2 2018 | $10,260,000 | +1.8% | 608,189 | +18.2% | 0.19% | -2.6% |
| Q1 2018 | $10,082,000 | -2.0% | 514,645 | +1.3% | 0.20% | +6.5% |
| Q4 2017 | $10,292,000 | +4.8% | 507,978 | -10.2% | 0.18% | +4.0% |
| Q3 2017 | $9,823,000 | +40.3% | 565,529 | +3.5% | 0.18% | +32.1% |
| Q2 2017 | $7,002,000 | -22.4% | 546,200 | -21.6% | 0.13% | -15.2% |
| Q1 2017 | $9,026,000 | +30.6% | 696,445 | -0.5% | 0.16% | +31.7% |
| Q4 2016 | $6,913,000 | +6.3% | 699,729 | +29.9% | 0.12% | -4.0% |
| Q3 2016 | $6,506,000 | +522.6% | 538,543 | +344.9% | 0.12% | +495.2% |
| Q2 2016 | $1,045,000 | +49.7% | 121,045 | +64.3% | 0.02% | +50.0% |
| Q1 2016 | $698,000 | -43.2% | 73,681 | +4.0% | 0.01% | -44.0% |
| Q4 2015 | $1,228,000 | +89.2% | 70,863 | +46.6% | 0.02% | +92.3% |
| Q3 2015 | $649,000 | -39.1% | 48,324 | +2.5% | 0.01% | -31.6% |
| Q2 2015 | $1,065,000 | – | 47,167 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |